TSHA
Taysha Gene Therapies, Inc.Company with tickers: TSHA
Market Cap
$1.99B
Shares Outstanding
287,361,020
CIK
1806310
CUSIP
877619106
13F Activity (30d)
2 filings
1 filers
Website
Visit website
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | $0 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Revenue (ASC 606) | — | ||||
| Interest & Dividend Income | — | ||||
| Net Interest Income | — | ||||
| Noninterest Income | — | ||||
| Total Net Revenue | — | ||||
| Premiums Earned (Net) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $43,486,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Research & Development | $33,809,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Operating Income | $-43,486,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Net Income | $-42,410,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| EPS (Basic) | $-0.12 | USD/shares | 2026-03-31 | 10-Q | 2026-05-06 |
| EPS (Diluted) | $-0.12 | USD/shares | 2026-03-31 | 10-Q | 2026-05-06 |